Whalegun
Home

Akebia Therapeutics AKBA spent $260K on lobbying in Q2 2024 · Health Issues, Medicare

Trade details

Type
Lobbying report
Amount
$260,000
Quarter
Q2 2024
Stock
Akebia Therapeutics AKBA
Client
Akebia Therapeutics
Reported
24/07/22

Down 29.7% from last quarter

What else happened in Akebia Therapeutics around then

Filed or reported within 30 days of the trade day · 24/05/31~24/07/30

Akebia Therapeutics's other lobbying reports

  • Akebia Therapeutics

    LobbyingAkebia Therapeutics

    $360K

    Reported 07/20

  • Akebia Therapeutics

    LobbyingAkebia Therapeutics

    $60K

    Reported 07/20

  • Akebia Therapeutics

    LobbyingAkebia Therapeutics

    $60K

    Reported 07/13

  • Akebia Therapeutics

    LobbyingAkebia Therapeutics

    $480K

    Reported 04/20

  • Akebia Therapeutics

    LobbyingAkebia Therapeutics

    $60K

    Reported 04/20

Akebia Therapeutics AKBA spent $260K on lobbying in Q2 2024 · Health Issues, Medicare | Whalegun